Overview
Pharmaceutical

Kyowa Kirin Co.,Ltd.

Kyowa Kirin is a Japan-based global specialty pharmaceutical company focused on the research, development, manufacturing, and commercialization of prescription drugs. The company leverages proprietary antibody engineering technologies and diverse modalities to address unmet medical needs, with particular strengths in rare and intractable diseases, nephrology, and oncology. Its pipeline and marketed products are built on advanced biopharmaceutical and antibody drug platforms, targeting both domestic and international markets.

Market Cap
¥1,263B
US$8.06B
EV
¥1,023B
US$6.52B
Stock¥2,412.5▼-0.04%
US$1 = ¥156.80 (2026-10-23)
LTM EV/EBITDA
7.7
x
LTM EV/EBIT
9.9
x
LTM PER
15.5
x
LTM PBR
1.4
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-16.6%pt
1001
Oct 24, 25 – Oct 23, 26StockTOPIX
1Sep 2, 26Agreed with Trump admin on MFN US drug price cuts, raising 'drug loss' concerns
MC → EV Bridge
1,263BUS$8.06BMarket Cap26.1BUS$167M+ Debt265BUS$1.69B− Cash1.52BUS$9.72M− Inv. Sec.1,023BUS$6.52BEV
AI Briefing
Generating insights…
Performance & Balance
Revenue 5Y (¥B)
352US$2.25B'21/12398US$2.54B'22/12442US$2.82B'23/12496US$3.16B'24/12497US$3.17B'25/12
Net Income 5Y (¥B)
52.3US$334M'21/1253.6US$342M'22/1281.2US$518M'23/1259.9US$382M'24/1267.0US$428M'25/12
Capital Structure
97%
EquityD/E 0.03xDebt
Liquidity vs Debt 5Y (¥B)▲ Net Cash
CashInv. Sec.Debt
335US$2.14B'21/12339US$2.16B'22/12403US$2.57B'23/12245US$1.56B21.7US$138M'24/12219US$1.40B26.1US$167M'25/12
Shareholders
Top 10 hold 75.2%
1
Kirin Holdings Company,Limited
55.16%
2
The Master Trust Bank of Japan, Ltd. (Trust Account)
9.46%
3
Custody Bank of Japan, Ltd. (Trust Account)
4.44%
4
BNY GCM CLIENT ACCOUNT JPRD AC ISG (FE-AC; Standing Proxy: MUFG Bank, Ltd.)
1.37%
5
UBS AG LONDON A/C IPB SEGREGATED CLIENT ACCOUNT (Standing Proxy: Citibank, N.A., Tokyo Branch)
1.09%
6
JPMorgan Securities Japan Co., Ltd.
0.91%
7
Natixis Securities Co., Ltd.
0.73%
8
STATE STREET BANK AND TRUST COMPANY 505301 (Standing Proxy: Mizuho Bank, Ltd.)
0.69%
9
JP MORGAN CHASE BANK 385781 (Standing Proxy: Mizuho Bank, Ltd.)
0.67%
10
STATE STREET BANK AND TRUST COMPANY 505001 (Standing Proxy: Mizuho Bank, Ltd.)
0.63%
Management
12 officers
Masashi MIYAMOTO
Representative Director, Chairman
Apr 1985 Joined Kirin Brewery Co., Ltd. (now Kirin Holdings Company, Limited) Apr 2011 Head of Regulatory Affairs Department, Quality Assurance Division, Kyowa Hakko Kirin Co., Ltd. (now Kyowa Kirin Co., Ltd.) Mar 2012 Executive Officer, Head of Regulatory Affairs Department, Quality Assurance Division, the Company Jul 2014 Executive Officer, Head of Product Portfolio Strategy Department and Head of Regulatory Affairs Department, Quality Assurance Division, the Company Apr 2015 Executive Officer, Head of Product Portfolio Strategy Department, the Company Mar 2017 Director, Managing Executive Officer, Head of Product Portfolio Strategy Department, the Company Apr 2017 Director, Managing Executive Officer, Head of Corporate Strategy Planning Department, the Company Mar 2018 Representative Director, President, the Company Apr 2024 Representative Director, President, Chief Executive Officer (CEO), the Company Mar 2025 Representative Director, Chairman, Chief Executive Officer (CEO), the Company (current) Mar 2026 Representative Director, Chairman, the Company
1959-07-16
Abdul MALIK
Representative Director, President, Chief Executive Officer (CEO)
Jan 1999 Global Marketing Director, Diabetes, Hoechst Marion Roussel Ltd. (presently Sanofi-Aventis Pharma AG) Jan 2005 Senior Global Brand Director, Diabetes, Novartis Pharma AG Dec 2007 EMEA Business Unit Head, Genzyme Corp. Jan 2009 Vice President, Commercial Operations, Japan, Asia-Pacific, Australia and China, Genzyme Corp. Jan 2011 Vice President, Head of Global Marketing, Rare Diseases, Genzyme Corp. Jul 2013 Vice President and General Manager, Endocrinology and Cardiology, Rare Diseases, Genzyme USA Sep 2014 Executive Vice President, Head of Global Marketing, Vifor Pharma Ltd Mar 2018 Executive Vice President, Rare Disease Head, Kyowa Kirin International plc Apr 2019 President, Kyowa Kirin International plc Jan 2023 Managing Executive Officer, Deputy Head of Overseas Business, Kyowa Kirin Co., Ltd. Mar 2023 Managing Executive Officer, Head of Overseas Business, the Company Apr 2024 Managing Executive Officer, Chief International Business Officer (CIBO), the Company Mar 2025 Representative Director, President, Chief Operating Officer (COO), the Company (current) Mar 2026 Representative Director, President, Chief Executive Officer (CEO), the Company
1967-05-14
Takemi YAMASHITA
Director, Vice President, Chief Science Officer (CSciO)
Apr 1987 Joined Kirin Brewery Co., Ltd. (now Kirin Holdings Company, Limited) Apr 2010 Director, Next-Generation Research Laboratories, Research Division, Kyowa Hakko Kirin Co., Ltd. (now Kyowa Kirin Co., Ltd.) Apr 2012 Head of Research Planning Department, Research Division, the Company Apr 2014 Head of Drug Discovery Platform Research Laboratories, Research Function Unit, Research and Development Division, the Company Apr 2015 Head of Regulatory Affairs Department, Quality Assurance Division, the Company Mar 2017 Executive Officer, Head of Regulatory Affairs Department, Quality Assurance Division, the Company Mar 2019 Executive Officer, Head of Corporate Strategy Planning Department, the Company Mar 2021 Managing Executive Officer, Head of Corporate Strategy Planning Department, the Company Apr 2022 Managing Executive Officer, Head of Strategy Division, the Company Mar 2023 Director, Senior Managing Executive Officer, Head of Strategy Division, the Company Apr 2023 Director, Senior Managing Executive Officer, the Company Apr 2024 Director, Senior Managing Executive Officer, Chief Medical Officer (CMO), the Company Mar 2025 Director, Vice President, Chief Medical Officer (CMO), the Company (current) Mar 2026 Director, Vice President, Chief Science Officer (CScO), the Company
1961-11-30
Takashi OYAMADA
Director
Apr 1979 Joined The Mitsubishi Bank, Ltd. (now MUFG Bank, Ltd.) Jan 2006 Executive Officer, The Bank of Tokyo-Mitsubishi UFJ, Ltd. (now MUFG Bank, Ltd.) Jun 2009 Managing Director, The Bank of Tokyo-Mitsubishi UFJ, Ltd.; Director, Mitsubishi UFJ Financial Group, Inc. May 2012 Managing Executive Officer, The Bank of Tokyo-Mitsubishi UFJ, Ltd. May 2013 Senior Managing Executive Officer, The Bank of Tokyo-Mitsubishi UFJ, Ltd. Jun 2014 Deputy President, Representative Director, The Bank of Tokyo-Mitsubishi UFJ, Ltd. Jun 2015 Director, Representative Executive Officer and Deputy President, Group COO, Mitsubishi UFJ Financial Group, Inc. Apr 2016 President, Representative Director, The Bank of Tokyo-Mitsubishi UFJ, Ltd.; Director, Mitsubishi UFJ Financial Group, Inc. Jun 2017 Senior Advisor, The Bank of Tokyo-Mitsubishi UFJ, Ltd. (current) Jun 2018 Director and Vice Chairman, Japan Institute of International Affairs (current) Jun 2018 Chairman, The Mitsubishi Economic Research Institute (current) Dec 2018 Outside Director, Mitsubishi Research Institute DCS Co., Ltd. (current) Jun 2019 Outside Director, Mitsubishi Electric Corporation; Outside Director, Mitsukoshi Isetan Holdings Ltd. Mar 2021 Outside Director, the Company (current)
1955-11-02
Yoshihisa SUZUKI
Director
Apr 1979 Joined ITOCHU Corporation Jun 2003 Executive Officer, Head of Aerospace and Electronics Division, ITOCHU Corporation Apr 2006 Managing Executive Officer, EVP and CAO, ITOCHU International Inc., ITOCHU Corporation Apr 2007 President and CEO, ITOCHU International Inc. Jun 2011 Deputy President, Representative Director, JAMCO Corporation Jun 2012 President and CEO, Representative Director, JAMCO Corporation Jun 2016 Representative Director, Senior Managing Executive Officer, ITOCHU Corporation Apr 2018 President, COO, Representative Director, ITOCHU Corporation Apr 2020 President, COO, Representative Director, and CDO and CIO, ITOCHU Corporation Apr 2021 Vice Chairman, Director, ITOCHU Corporation Mar 2022 Outside Director, the Company (current) Apr 2022 Vice Chairman, ITOCHU Corporation Jun 2022 Outside Director, OMRON Corporation (current) Apr 2023 Senior Managing Director, ITOCHU Corporation Apr 2024 Advisor, ITOCHU Corporation (current) Jun 2025 Outside Director, JFE Holdings, Inc. (current)
1955-06-21
Rumiko NAKATA
Director
Apr 1979 Joined Esso Sekiyu K.K. Apr 1996 Joined Sangyo Shakai Kenkyu Center Co., Ltd. Apr 2000 Joined Pfizer Japan Inc. Dec 2011 Head of Human Resources and General Affairs, Pfizer Japan Inc. Mar 2012 Executive Officer, Pfizer Japan Inc. Jan 2014 Director and Executive Officer, Pfizer Japan Inc. Mar 2018 Executive Officer, in charge of Diversity Promotion, Mitsubishi Chemical Holdings Corporation Apr 2019 Managing Executive Officer, in charge of Human Resources, Mitsubishi Chemical Holdings Corporation Apr 2020 Director, Managing Executive Officer, in charge of General Affairs, Public Relations and Human Resources, Mitsubishi Chemical Holdings Corporation Apr 2022 Director, Mitsubishi Chemical Holdings Corporation Mar 2023 Outside Director, the Company (current) Jun 2024 Outside Director, Denka Company Limited (current)
1956-04-06
Yukiko ITO
Director
Apr 2006 Full-time Lecturer, Faculty of Economics, Tokyo Keizai University Apr 2009 Associate Professor, Field of Economics, Faculty of Humanities and Social Sciences, Tokyo Gakugei University Jul 2015 Member, Committee for Economic and Fiscal Structural Reform, Cabinet Office Apr 2018 Professor, Department of Policy Studies, School of Political Science and Economics, Tsuda University Jul 2018 Member, Pharmaceutical and Medical Device System Subcommittee, Pharmaceutical Affairs Council, Ministry of Health, Labour and Welfare (current) Apr 2024 Director, Japan Community Health Care Organization (current) Jun 2024 Director, Pfizer Health Research Foundation (current) Mar 2025 Outside Director, the Company (current) Apr 2025 Professor, Graduate School of Business and Commerce, Keio University (current)
1978-09-16
Kenji SHIBATA
Director, Full-time Audit and Supervisory Committee Member
Apr 1992 Joined Kyowa Hakko Kogyo Co., Ltd. (now Kyowa Kirin Co., Ltd.) Apr 2004 Senior Researcher, the Company Jul 2009 Manager, Research Planning Department, Research Division, Kyowa Hakko Kirin Co., Ltd. (now Kyowa Kirin Co., Ltd.) Apr 2012 Group Leader, Exploratory Research Laboratories, Research Division, the Company Apr 2014 Group Leader, Research and Development Planning Department, Research and Development Division, the Company Apr 2016 Senior Manager, Research and Development Planning Department, Research and Development Division, the Company Apr 2018 Head of Research and Development Planning Department, Research and Development Division, the Company Mar 2021 Executive Officer, Head of Corporate Audit Department, the Company (current) Mar 2026 Director, Full-time Audit and Supervisory Committee Member, the Company
1966-09-20
Hiroshi KANNO
Director, Audit and Supervisory Committee Member
Apr 1983 Joined Nikken Sekkei Ltd. Aug 1991 Joined The Boston Consulting Group, Inc. (now Boston Consulting Group G.K.) Jan 2000 Partner and Managing Director, Boston Consulting Group Jul 2008 Professor, Graduate School of International Corporate Strategy, Hitotsubashi University Jun 2011 Outside Director, Omron Healthcare Co., Ltd. Apr 2012 Dean, Graduate School of International Corporate Strategy, Hitotsubashi University Oct 2012 Outside Director, Japan Display Inc. Jun 2014 Outside Director, WOWOW Inc. Jun 2015 Outside Audit & Supervisory Board Member, Stanley Electric Co., Ltd. Mar 2016 Outside Director, Mitsui Ocean Development & Engineering Co., Ltd. Sep 2016 Professor, Graduate School of Business Administration, Waseda University (current) Dec 2016 Director, Uni-Charm Kyoshin Foundation (current) Sep 2017 Outside Director, ERI Holdings Co., Ltd. Sep 2018 Director, Center for Business and Finance, Waseda University (current) Apr 2020 Visiting Professor, The Open University of Japan Jul 2022 Outside Director, Laboro.AI Inc. (current) Feb 2023 Visiting Professor, Department of Management, Aalto University School of Business (Finland) Mar 2025 Outside Director, the Company (current) Mar 2026 Outside Director, the Company, Audit and Supervisory Committee Member
1958-11-14
Daisuke FUJIWARA
Director
Apr 1995 Joined Kirin Brewery Co., Ltd. (now Kirin Holdings Company, Limited) Nov 1999 Received Ph.D. (Agriculture) Feb 2005 Visiting Researcher, Laboratory for Allergy and Immunology, RIKEN Sep 2005 Postdoctoral Fellow, David Geffen School of Medicine, University of California, Los Angeles (USA) Nov 2007 Senior Researcher, Institute of Basic Technology Research, Kirin Holdings Company, Limited May 2014 Part-time Lecturer, Graduate School of Agricultural and Life Sciences, The University of Tokyo (current) Mar 2021 General Manager, Health Science Business Division, Kirin Holdings Company, Limited Apr 2023 Executive Officer, Head of Health Science Research Institute, Kirin Holdings Company, Limited Mar 2025 Director, Kyowa Kirin Co., Ltd. (current) Mar 2025 Managing Executive Officer, Head of R&D Division, Kirin Holdings Company, Limited (current)
1970-10-01
Yoko WACHI
Director, Audit and Supervisory Committee Member
Apr 1989 Registered as attorney-at-law (Daiichi Tokyo Bar Association); joined Kajitani Sogo Law Offices Apr 2006 Mediation Committee Member, Tokyo Family Court (current) Jun 2015 Outside Audit & Supervisory Board Member, Nichias Corporation Mar 2016 Outside Audit & Supervisory Board Member, Otsuka Holdings Co., Ltd. Jan 2019 Partner, Kajitani Sogo Law Offices (current) Apr 2019 Vice President, Tokyo Family Mediation Association Jun 2019 Outside Director, Nichias Corporation (current) Jun 2023 Outside Director, S.T. Corporation (current) Mar 2025 Outside Audit & Supervisory Board Member, Kyowa Kirin Co., Ltd. (current) Mar 2026 Outside Director, the Company, Audit and Supervisory Committee Member
1960-04-29
Kohei KAN
Director, Audit and Supervisory Committee Member
Sep 1986 Registered as Certified Public Accountant Apr 1987 Joined Sanda Accounting Corporation (now Deloitte Touche Tohmatsu LLC) Jun 1998 Partner, Deloitte Touche Tohmatsu Nov 2013 Board Member, Deloitte Tohmatsu Group and Deloitte Touche Tohmatsu LLC Nov 2015 Chief Executive, Deloitte Touche Tohmatsu LLC Jun 2018 Senior Advisor, Deloitte Tohmatsu LLC Sep 2018 Audit and Assurance Leader, Deloitte Asia Pacific Limited Jan 2020 Senior Advisor, Deloitte Asia Pacific Limited Oct 2020 Head of Kohei Kan Certified Public Accountant Office (current) Nov 2020 Board Member, International Federation of Accountants (IFAC) (current) Jan 2022 Senior Advisor, Japanese Institute of Certified Public Accountants (current) Jun 2022 Outside Director, Olympus Corporation (current) Mar 2026 Outside Director, Kyowa Kirin Co., Ltd., Audit and Supervisory Committee Member
1960-03-07
Large Shareholding Reports
No filings
Disclosures
No disclosures
Primary Source Filings
EDINET
2026-08-03
Semi-Annual Securities Report
Period: Jan 2026 – Dec 2026
TDnet
2026-08-03
Q2 Earnings Flash
FY ending Dec 2026
TDnet
2026-05-07
Q1 Earnings Flash
FY ending Dec 2026
EDINETAmended
2026-03-23
Amended Securities Registration Statement
EDINET
2026-03-19
Securities Registration Statement
EDINET
2026-03-10
Annual Securities Report
Period: Jan 2025 – Dec 2025
EDINET
2026-02-01
中期経営計画
FY ending Dec 2025
EDINET
2026-02-01
中期経営計画
TDnet
2025-10-30
Q3 Earnings Flash
FY ending Dec 2025
EDINET
2025-07-31
Semi-Annual Securities Report
Period: Jan 2025 – Dec 2025
TDnet
2025-05-01
Q1 Earnings Flash
FY ending Dec 2025
EDINETAmended
2025-03-21
Amended Securities Registration Statement
EDINET
2025-03-19
Securities Registration Statement
EDINET
2025-03-11
Annual Securities Report
Period: Jan 2024 – Dec 2024
EDINET
2024-08-01
Semi-Annual Securities Report
Period: Jan 2024 – Dec 2024
EDINET
2024-05-07
Quarterly Securities Report
Period: Jan 2024 – Mar 2024
EDINET
2024-03-12
Annual Securities Report
Period: Jan 2023 – Dec 2023
EDINET
2023-11-01
Quarterly Securities Report
Period: Jul 2023 – Sep 2023
EDINET
2023-08-03
Quarterly Securities Report
Period: Apr 2023 – Jun 2023
EDINET
2023-05-10
Quarterly Securities Report
Period: Jan 2023 – Mar 2023
EDINET
2023-03-09
Annual Securities Report
Period: Jan 2022 – Dec 2022
EDINET
2022-11-04
Quarterly Securities Report
EDINET
2022-08-04
Quarterly Securities Report
EDINET
2022-05-10
Quarterly Securities Report
EDINET
2022-03-08
Annual Securities Report
EDINET
2021-11-01
Quarterly Securities Report
EDINET
2021-08-03
Quarterly Securities Report
EDINET
2021-05-06
Quarterly Securities Report
EDINET
2021-03-09
Annual Securities Report
EDINET
2021-02-04
中期経営計画
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →